Pipeline
ABL111
HomePipelineABL111
-
- Pipeline
- ABL111
-
- Program Target
- Claudin18.2x4-1BB
-
- Disease Indication
- Solid Tumor
-
- Development Stage
- Clinical Development
(Phase 1)
- Summary
- ABL111 is a bispecific antibody that targets Claudin18.2, a tumor antigen overexpressed in gastric- and pancreatic-specific cancer, and 4-1BB, a co-stimulatory receptor with the ability to induce potent anti-tumor activity. To minimize the usual toxicity associated with monospecific 4-1BB based treatments, ABL111 only activates the 4-1BB pathway when engaged with Claudin 18.2, thus triggering T cell activation and enhancing anti-tumor immunity while minimizing toxicity. ABL111 shows superior anti-tumor activity in an animal model system compared to Claudin18.2 alone, 4-1BB alone, and the combination of both Claudin18.2 and 4-1BB, with immunological memory resistant to any possible recurrence of the cancer cells.
Structure and Mechanism of Action
Claudin18.2 Dependent 4-1BB Activation
Superior Anti-Tumor Effect with Immunological Memory
Increase of effector memory CD8+ T cells and soluble 4-1BB
